{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000140","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.443368+00:00","generated_at":"2026-05-30T15:09:13.069155+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Exelixis wins patent case against MSN; generic launch blocked until Jan 2030","bullets":["Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.","Court found MSN's ANDA product infringes those three patents; separate patent 11,298,349 (exp 2032) was not infringed.","Final judgment due Oct 22; FDA cannot approve MSN's generic before Jan 15, 2030 at the earliest.","Ruling protects Exelixis' cabozantinib franchise from generic entry for over five additional years."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000140","json":"https://secwatch.observer/filing/0000939767-24-000140.json","markdown":"https://secwatch.observer/filing/0000939767-24-000140.md","text":"https://secwatch.observer/filing/0000939767-24-000140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000140/0000939767-24-000140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000140/exel-20241015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:09:13.069155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}